Making a case for domperidone in the treatment of gastrointestinal motility disorders

Current Opinion in Pharmacology

Volumn 6, Issue 6, 2006, Pages 571-576

  Ahmad, Naveed ^a   Keith Ferris, Jeanne ^b   Gooden, Elizabeth ^b   Abell, Thomas ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b Gastroparesis and Dymotilities Association International   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYROPHENONE DERIVATIVE; CISAPRIDE; DOMPERIDONE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ERYTHROMYCIN; METOCLOPRAMIDE; PLACEBO; PROKINETIC AGENT;

ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; DRUG ADMINISTRATION ROUTE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL MOTILITY DISORDER; HUMAN; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSON DISEASE; PRIORITY JOURNAL; QT PROLONGATION; STOMACH DISEASE; STOMACH PARESIS; SUDDEN DEATH; TARDIVE DYSKINESIA;

DOMPERIDONE; DOPAMINE ANTAGONISTS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; HUMANS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 33750511570     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.07.004     Document Type: Article

References (52)

1. Horowitz M., Su Y.C., Rayner C.K., and Jones K.L. Gastroparesis: prevalence, clinical significance and treatment. Can J Gastroenterol 15 (2001) 805-813
2. Soykan I., Sivri B., Sarosiek I., Kierran B., and McCallum R.W. Demography, clinical characteristics, psychological profiles, treatment and long-term follow-up of patients with gastroparesis. Dig Dis Sci 43 (1998) 2398-2404
3. Hoogerwerf W.A., Pasricha P.J., Kalloo A.N., and Schuster M.M. Pain: the overlooked symptom in gastroparesis. Am J Gastroenterol 94 (1999) 1029-1033
4. Parkman H.P., and Schwartz S.S. Esophagitis and gastroduodenal disorders associated with diabetic gastroparesis. Arch Intern Med 147 (1987) 1477-1480
5. Blam M.E., and Lichtenstein G.R. A new endoscopic technique for the removal of gastric phytobezoars. Gastrointest Endosc 52 (2000) 404-408
6. Brogden R.N., Carmine A.A., Heel R.C., Speight T.M., and Avery G.S. Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs 24 (1982) 360-400
7. Schuurkes J.A., and Van Nueten J.M. Control of gastroduodenal coordination: dopaminergic and cholinergic pathways. Scand J Gastroenterol Suppl 92 (1984) 8-12
8. Niemegeers C.J., Schellekens K.H., and Janssen P.A. The antiemetic effects of domperidone, a novel potent gastrokinetic. Arch Int Pharmacodyn Ther 244 (1980) 130-140
9. Shuto K., Shiozaki Z., Kojima T., and Tanaka M. Antagonism of KW-5338 (domperidone) against emesis and depression of intestinal motility induced by L-DOPA. J Pharmacobiodyn 3 (1980) 709-714
10. Besser G.M., Yeo T., Delitala G., and Grossman A.B. Alteration of prolactin secretion by centrally acting drugs. Adv Biochem Psychopharmacol 24 (1980) 399-406
11. Carter D.A., Pennington J.M., and Whitehead S.A. In-vivo and in-vitro effects of domperidone on the release of prolactin and LH in male and female rats. J Reprod Fertil 64 (1982) 191-197
12. Cocchi D., Gil-Ad I., Parenti M., Stefanini E., Locatelli V., and Muller E.E. Prolactin-releasing effect of a novel anti-dopaminergic drug, domperidone, in the rat. Neuroendocrinology 30 (1980) 65-69
13. Heykants J., Hendriks R., Meuldermans W., Michiels M., Scheygrond H., and Reyntjens H. On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet 6 (1981) 61-70
14. Huang Y.C., Colaizzi J.L., Bierman R.H., Woestenborghs R., and Heykants J.J. Pharmacokinetics and dose proportionality of domperidone in healthy volunteers. J Clin Pharmacol 26 (1986) 628-632
15. Meuldermans W., Hurkmans R., Swysen E., Hendrickx J., Michiels M., Lauwers W., and Heykants J. On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man. Eur J Drug Metab Pharmacokinet 6 (1981) 49-60
16. Horowitz M., Harding P.E., Chatterton B.E., Collins P.J., and Shearman D.J. Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy. Dig Dis Sci 30 (1985) 1-9
17. Patterson D., Abell T., Rothstein R., Koch K., and Barnett J. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 94 (1999) 1230-1234
18. Koch K.L., Stern R.M., Stewart W.R., and Vasey M.W. Gastric emptying and gastric myoelectrical activity in patients with diabetic gastroparesis: effect of long-term domperidone treatment. Am J Gastroenterol 84 (1989) 1069-1075
19. Ajaz A, Alam S, Chaudhary S: Metoclopramide and domperidone in the treatment of gastroparesis. (Protocol). The Cochrane Database of Systematic Reviews 2003, 3: Art No: CD004777. [DOI:10.1002/14651858.CD004777].
20. US Food and Drug Administration: Talk paper. "FDA warns against women using unapproved drug, domperidone, to increase milk production." [http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01292.html].
21. Bruera E., Villamayor R., Roca E., Barugel M., Tronge J., and Chacon R. Q-T interval prolongation and ventricular fibrillation with i.v. domperidone. Cancer Treat Rep 70 (1986) 545-546
22. Osborne R.J., Slevin M.L., Hunter R.W., and Hamer J. Cardiotoxicity of intravenous domperidone. Lancet 2 (1985) 385
23. Cameron H.A., Reyntjens A.J., and Lake-Bakaar G. Cardiac arrest after treatment with intravenous domperidone. Br Med J (Clin Res Ed) 290 (1985) 160
24. Quinn N., Parkes D., Jackson G., and Upward J. Cardiotoxicity of domperidone. Lancet 2 (1985) 724
25. Osborne R.J., Slevin M.L., Hunter R.W., and Hamer J. Cardiac arrhythmias during cytotoxic chemotherapy: role of domperidone. Cardiac arrest after treatment with intravenous domperidone. Hum Toxicol 4 (1985) 617-626
26. Roussak J.B., Carey P., and Parry H. Cardiac arrest after treatment with intravenous domperidone. Br Med J (Clin Res Ed) 289 (1984) 1579
27. Giaccone G., Bertetto O., and Calciati A. Two sudden deaths during prophylactic antiemetic treatment with high doses of domperidone and methylprednisolone. Lancet 2 (1984) 1336-1337
28. Joss R.A., Goldhirsch A., Brunner K.W., and Galeazzi R.L. Sudden death in cancer patient on high-dose domperidone. Lancet 1 (1982) 1019
29. Rocha C.M., and Barbosa M.M. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol 26 (2005) 720-723
30. Caruso U., D'Iddio S., Cravotto E., Pesce S., Betti I., Ruscitto G., Ecari U., and Sabrie A.M. Domperidone as an anti-emetic in antineoplastic chemotherapy. Minerva Chir 36 (1981) 787-791
31. Dodds L.J. The control of cancer chemotherapy-induced nausea and vomiting. J Clin Hosp Pharm 10 (1985) 143-166
32. Cunningham D., Evans C., Gazet J.C., Ford H., Pople A., Dearling J., Chappell D., and Coombes C. Comparison of antiemetic efficacy of domperidone, metoclopramide, and dexamethasone in patients receiving outpatient chemotherapy regimens. Br Med J (Clin Res Ed) 295 (1987) 250
33. Mary Ross Southworth: Post-marketing review of movement disorders and neuroleptic malignant syndrome associated with metoclopramide. FDA docket. [http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4167S1_02_03-FDA-SOUTHWORTH.ppt].
34. Shaffer D., Butterfield M., Pamer C., and Mackey A.C. Tardive dyskinesia and metoclopramide use: effects of cisapride market withdrawal. J Am Pharm Assoc 44 (2004) 661-665
35. Grimes J.D., and Magner P.O. Safety of domperidone in metoclopramide-induced parkinsonism. Arch Neurol 41 (1984) 363-364
36. Soykan I., Sarosiek I., and McCallum R.W. The effect of chronic oral domperidone therapy on GI symptoms, gastric emptying, and quality of life in patients with gastroparesis. Am J Gastroenterol 92 (1997) 976-980
37. Agid Y., Quinn N., and Lhermitte F. Long-term results of treatment of Parkinson's disease with bromocriptine and domperidone. Rev Neurol (Paris) 137 (1981) 49-51
38. Quinn N., Illas A., Lhermitte F., and Agid Y. Bromocriptine and domperidone in the treatment of Parkinson disease. Neurology 31 (1981) 662-667
39. Soykan I., Sarosiek I., Shifflett J., Wooten G.F., and McCallum R.W. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease. Mov Disord 12 (1997) 952-957
40. Baguley W.A., Hay W.T., Mackie K.P., Cheney F.W., and Cullen B.F. Cardiac dysrhythmias associated with the intravenous administration of ondansetron and metoclopramide. Anesth Analg 84 (1997) 1380-1381
41. Parkman H.P., Hasler W.L., and Fisher R.S. American gastroenterological association: American gastroenterological association medical position statement: diagnosis and treatment of gastroparesis. Gastroenterology 127 (2004) 1589-1591. A thorough review of the diagnosis and treatment of gastroparesis through the early years of the 2000s.
42. Abell T.L., Bernstein V.K., Cutts T., Farrugia G., Forster J., Hasler W.L., McCallum R.W., Olden K.W., Parkman H.P., Parrish C.R., et al. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil 18 (2006) 263-283. An update featuring a multi-disciplinary approach to the many clinical aspects of the treatment of gastroparesis through 2005.
43. Jones M.P. Access options for withdrawn motility-modifying agents. Am J Gastroenterol 97 (2002) 2184-2188
44. Nagler J., and Miskovitz P. Clinical evaluation of domperidone in the treatment of chronic postprandial idiopathic upper gastrointestinal distress. Am J Gastroenterol 76 (1981) 495-499
45. Watts G.F., Armitage M., Sinclair J., and Hill R.D. Treatment of diabetic gastroparesis with oral domperidone. Diabet Med 2 (1985) 491-492
46. Champion M.C., Gulenchyn K., and O'Leary T. Domperidone (Motilium) improves symptoms and solid phase gastric emptying in diabetic gastroparesis. Am J Gastroenterol 82 (1987) 975
47. Davis R.H., Clench M.H., and Mathias J.R. Effects of domperidone in patients with chronic unexplained upper gastrointestinal symptoms: a double-blind, placebo-controlled study. Dig Dis Sci 33 (1988) 1505-1511
48. Koch K.L., Stern R.M., Stewart W.R., and Vasey M.W. Gastric emptying and gastric myoelectrical activity in patients with diabetic gastroparesis: effect of long-term domperidone treatment. Am J Gastroenterol 84 (1989) 1069-1075
49. Soykan I., Sarosiek I., and McCallum R.W. The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis. Am J Gastroenterol 92 (1997) 976-980
50. Silvers D., Kipnes M., Broadstone V., Patterson D., Quigley E.M., McCallum R., Leidy N.K., Farup C., Liu Y., and Joslyn A. Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group. Clin Ther 20 (1998) 438-453
51. Dumitrascu D.L., and Weinbeck M. Domperidone versus metoclopramide in the treatment of diabetic gastroparesis. Am J Gastroenterol 95 (2000) 316-317
52. Franzese A., Borrelli O., Corrado G., Rea P., Di Nardo G., Grandinetti A.L., Dito L., and Cucchiara S. Domperidone is more effective than cisapride in children with diabetic gastroparesis. Aliment Pharmacol Ther 16 (2002) 951-957